NK/T cell lymphomas have a distinct immunophenotype, and PD-1 blockade has shown some efficacy in relapsed or refractory NK/T cell lymphomas [89]. This evidence concerns the gene PDCD1 and T-cell non-Hodgkin lymphoma.